Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (Study P02733AM4)(COMPLETED)
This study has been completed.
Sponsor:
Schering-Plough
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00759109
First received: August 26, 2008
Last updated: April 27, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did not respond to previous combined therapy with interferon alfa + ribavirin or peginterferon alfa + ribavirin or to interferon alfa monotherapy and with a high proliferation rate before entering the study. The duration of treatment will be 3 years, and the follow-up period will be 2 years.
| Condition | Intervention | Phase |
|---|---|---|
|
Carcinoma, Hepatocellular |
Biological: Peginterferon alfa-2b, PegIntron, Pegylated Alfa-2b (SCH 054031) Other: Observation (no treatment) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Long-term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy |
Resource links provided by NLM:
Genetics Home Reference related topics:
North American Indian childhood cirrhosis
U.S. FDA Resources
Further study details as provided by Schering-Plough:
Primary Outcome Measures:
- Number of Participants With the Development of Hepatocellular Carcinoma (HCC) [ Time Frame: During 3 years of treatment and 2 years of follow-up ] [ Designated as safety issue: No ]
Participants were tested for focal lesions by liver ultrasound and for AFP levels every 6 months the during study (treatment and follow-up).
The development of hepatocellular carcinoma was determined by:
- the appearance of a focal lesion detected by liver ultrasound with metastases confirmed by fine needle biopsy, or
- the appearance of a focal lesion detected by ultrasound + alphafetoprotein (AFP) levels in blood >400 ng/mL.
Secondary Outcome Measures:
- Number of Participants With Development of Hepatic Decompensation [ Time Frame: Baseline, During 3 years of treatment and 2 years of follow-up ] [ Designated as safety issue: No ]The development of hepatic decompensation, defined as worsening of the hepatic function as measured by Child Pugh Score. The Child Pugh score was calculated based on biochemical changes (changes in serum albumin, serum bilirubin, prothrombin time) and clinical impairment (ascites, encephalopathies) or both. Each of the 5 parameters was scored from 1-3, and the Child Pugh Score represented the total score. The maximum score was 15, and a score of 10-15 represents the worst outcome and a life expectancy of 1-3 years.
- Survival Time of Participants [ Time Frame: During 3 years of treatment and 2 years of follow-up ] [ Designated as safety issue: No ]Survival time was defined as time from screening visit to the death of the participant and was studied with Kaplan-Meier and Log-rank tests. If a participant did not die, he or she was censored with the last available date.
- Number of Patients With a Virological Response Rate [ Time Frame: Baseline and every year during 3 years of treatment ] [ Designated as safety issue: No ]Virological Response rate was measured by the disappearance of Hepatitis C Virus from serum. Serum samples from participants were analyzed for the presence of HCV-RNA using a qualitative polymerase chain reaction (PCR).
- Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) [ Time Frame: Baseline and at 18 months of treatment ] [ Designated as safety issue: No ]
PCNA-LI was measured at baseline and at 18 months of treatment, and the change in PCNA-LI was calculated.
To measure PCNA-LI, liver tissue samples obtained from biopsies were fixed and immunostained to detect PCNA. PCNA-LI is the percentage of immunohistochemically stained (PCNA positive) cells in 1,000 HCC cells counted. A higher PCNA-LI indicates a worse outcome.
| Enrollment: | 150 |
| Study Start Date: | January 2002 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm A - PegIntron
Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
|
Biological: Peginterferon alfa-2b, PegIntron, Pegylated Alfa-2b (SCH 054031)
Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
|
|
No Intervention: Arm B - Control
Participants randomized to Arm B were under observation and received no treatment.
|
Other: Observation (no treatment)
No treatment was given to participants enrolled in the control arm (Arm B).
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Cirrhotic participants, both sexes, Child Pugh A, B, HCV-RNA positive, age < 70 years
- Participants non-responders to IFN + Ribavirin or PegIFN + Ribavirin or IFN monotherapy
- Pre-therapy liver biopsy (< 36 months) with PCNA-LI > 2.0
- Fibrosis score 5-6 (Ishak)
Initial portal hypertension, such as gastroesophageal varices or one of the following US sign:
- Collateral circles
- Spleen longitudinal diameter > 12 cm
- Portal vein diameter at hilus > 12 mm
- Portal flow > 12 cm/sec
- Participants must have the following minimum hematologic and biochemical criteria:
- Hemoglobin >= 11 g/dL
- Granulocyte count > 1,000/mm^3
- Platelets > 70,000/mm^3
- Prothrombin activity > 50%
- Total bilirubin <3 mg/dL
- Albumin >= 3.5 g/dL
- Serum creatinine within normal limits
- Uric Acid within normal limits
- Thyroid Stimulating Hormone (TSH), within normal limits
- Antinuclear antibodies (ANA) < 1:160
- Written informed consent
- Women of childbearing potential must have a negative pregnancy test
- Acceptance of patients of both sexes of proper contraceptive measures for the study period
Exclusion Criteria:
- Pregnant or breast-feeding women
- Co-infection with HIV and/or HBV
- Autoimmune hepatitis or history of autoimmune disease
- Alcoholic liver disease
- Metabolic disease
- HCC
- Participants with liver and kidney transplants
- Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy
- Chronic renal failure or creatinine clearance < 50 mL/min
- Pre-existing thyroid disease unless it can be controlled with conventional treatment
- History or presence of psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt
- Epilepsy and/or compromised central nervous system (CNS) function
- Significant cardiovascular dysfunction within the previous 6 months before the study starts (eg, angina, congestive heart failure, recent myocardial infarction, moderate or severe hypertension, significant arrhythmia)
- Hemoglobinopathies
- Poorly controlled diabetes mellitus
- Chronic pulmonary disease (eg, chronic obstructive pulmonary disease)
- Clinical gout
- Hypersensitivity to interferons or any component of the drug
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough |
| ClinicalTrials.gov Identifier: | NCT00759109 History of Changes |
| Other Study ID Numbers: | P02733 |
| Study First Received: | August 26, 2008 |
| Results First Received: | March 24, 2011 |
| Last Updated: | April 27, 2011 |
| Health Authority: | Italy: Ministry of Health |
Additional relevant MeSH terms:
|
Carcinoma Hepatitis Hepatitis C Fibrosis Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections RNA Virus Infections Pathologic Processes |
Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Reaferon Interferon Alfa-2b Interferons Interferon-alpha Peginterferon alfa-2b Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antiviral Agents Anti-Infective Agents Angiogenesis Inhibitors |
ClinicalTrials.gov processed this record on May 19, 2013